SIGLEC1 and lung disorder: This concern could be addressed by using recently developed transgenic mice that specifically target TR-AMs (e.g., CD169-Cre) (62–64) or Mo-AMs (e.g., hCD68rtTA-tet-On-Cre) (31, 65) in the experimental lung disease models.